Mercaptopurina Silver

Mercaptopurine, the active ingredient in Mercaptopurina Silver, is an antimetabolite (purine analog) presented as an oral formulation for oral use. It is employed in the treatment of certain leukemias and inflammatory bowel diseases. GNH USA supplies Mercaptopurina Silver as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mercaptopurina Silver acts on rapidly dividing cells and immune pathways, making it useful in several hematologic and gastrointestinal conditions. Acute lymphoblastic leukemia: helps achieve and maintain remission in pediatric and adult patients. Maintenance therapy for leukemia: provides long‑term disease control after induction. Crohn's disease: reduces intestinal inflammation and induces clinical response. Ulcerative colitis: assists in attaining remission and decreasing steroid dependence.

Adverse reactions may occur with Mercaptopurina Silver and should be monitored.

Common Side Effects: - Nausea or vomiting. - Decreased appetite. - Mild infections such as upper respiratory tract infections. - Hair thinning or loss. - Skin rash or itching. - Fatigue.

Serious or Rare Side Effects: - Bone marrow suppression resulting in anemia, leukopenia, or thrombocytopenia. - Severe infections due to profound immunosuppression. - Hepatotoxicity with elevated liver enzymes or jaundice. - Pancreatitis presenting with abdominal pain. - Hypersensitivity reactions including fever and eosinophilia. - Development of secondary malignancies.

Before initiating therapy, clinicians should assess baseline laboratory values and patient history. - Monitor blood counts: perform regular CBC to detect marrow suppression. - Assess liver function: check transaminases and bilirubin periodically. - Adjust dose in renal impairment: consider reduced dosing if creatinine clearance is low. - Avoid use in known hypersensitivity: discontinue if allergic reactions occur. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Mercaptopurina Silver can interact with several medicines, altering efficacy or toxicity.

Major Interactions (Avoid): - Allopurinol: may increase mercaptopurine toxicity. - Azathioprine: additive myelosuppression due to shared metabolites. - TPMT deficiency (genetic): heightened risk of severe bone marrow suppression.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase risk of gastrointestinal irritation. - Warfarin: potential enhancement of anticoagulant effect, requiring INR monitoring.